Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after ...
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and ...
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
Children should have the freedom to focus on school, friendships, family, sports, birthdays, and simply growing up. Yet ...
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli ...
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results